首页 › 基金 › ORBIMED ADVISORS LLC › WST

ORBIMED ADVISORS LLC 对 WST 的持仓历史

WEST PHARMACEUTICAL SVSC INC · 医疗保健

ORBIMED ADVISORS LLC 在 Q2 2026 的 13F 申报中披露持有 WST(WEST PHARMACEUTICAL SVSC INC)70,600 股,市值约 US$25.3M,约占其申报组合的 0.51%,在其申报持仓中市值排名第 50 位。 ORBIMED ADVISORS LLC 于 Q2 2026 首次申报该持仓。

最新持仓 (Q2 2026)70.60K 股
申报持仓市值$25.35M
组合权重0.51%
首次申报Q2 2026
最近变动新进
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

ORBIMED ADVISORS LLC 对 WST 的持仓演变

ORBIMED ADVISORS LLC 于 Q2 2026 首次披露 WST 持仓:70,600 股(约 US$25.3M)。

逐季持仓明细

季度股数金额变化
Q2 2026 70.60K $25.35M 新进

关于 WST 与 13F 数据

WST(WEST PHARMACEUTICAL SVSC INC)属于医疗保健行业。我们追踪的基金中还有 35 只申报持有 WST,申报仓位最大的包括:Artisan Partners Limited Partnership (US$865.8M), GENERATION INVESTMENT MANAGEMENT LLP (US$728.2M), BROWN ADVISORY INC (US$386.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 WST 的基金

查看 WST 的全部基金持有人 →

常见问题

How long has ORBIMED ADVISORS LLC held WST?

ORBIMED ADVISORS LLC has disclosed WST holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is ORBIMED ADVISORS LLC's current position in WST?

As of Q2 2026, ORBIMED ADVISORS LLC holds 70.60K shares of WST (WEST PHARMACEUTICAL SVSC INC), valued at $25.35M, representing 0.51% of its reported portfolio and ranking #50.

Has ORBIMED ADVISORS LLC been buying or selling WST?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC newly opened its position in WST.

Which other funds hold WST?

Other major institutional holders of WST include Artisan Partners Limited Partnership, GENERATION INVESTMENT MANAGEMENT LLP, BROWN ADVISORY INC, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.